Onartuzumab
Onartuzumab
Onartuzumab (pronunciation: on-ar-tuz-u-mab) is a monoclonal antibody designed for the treatment of cancer. It is a therapeutic agent that targets the MET receptor, a protein often found in high levels on the surface of cancer cells.
Etymology
The name "Onartuzumab" is derived from the International Nonproprietary Names (INNs), where "onartu-" refers to the oncology target, "-zu-" indicates humanized antibody, and "-mab" is the suffix for monoclonal antibodies.
Mechanism of Action
Onartuzumab works by binding to the MET receptor on the surface of cancer cells, thereby inhibiting the receptor's activity. This can lead to a decrease in cancer cell growth and proliferation.
Clinical Trials
Onartuzumab has been studied in several clinical trials, including those for non-small cell lung cancer (NSCLC) and gastric cancer. However, the results have been mixed, and the drug is not currently approved for use.
Related Terms
External links
- Medical encyclopedia article on Onartuzumab
- Wikipedia's article - Onartuzumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski